No Data
No Data
Amgen (AMGN.US) and Astrazeneca (AZN.US) received breakthrough therapy designation from the FDA for their first-in-class therapy for treating COPD.
Two companies are planning to launch phase III clinical trials in COPD patients.
Despite Lower Earnings Than Five Years Ago, Amgen (NASDAQ:AMGN) Investors Are up 83% Since Then
Why It Might Not Make Sense To Buy Amgen Inc. (NASDAQ:AMGN) For Its Upcoming Dividend
What Eli Lilly, Novo Nordisk Earnings Reveal About the Future of GLP-1 Sales
About 73% of the S&P 500 Names Beat on EPS During the Week - Earnings Scorecard
Notable Analyst Calls This Week: Disney, Super Micro and Amgen Among Top Picks
Michael Tan053 : Moomoo informations updated surprisingly good
Michael Tan053 : Moomoo giving away free stocks for investment what good about stock after Monday collapses
Michael Tan053 : Fed Chairman cutting interest rates?
Paul Anthony : how take the time for your wonderful comments
山芭佬 :